Integrase inhibitors in the treatment of HIV-1 infection

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2485-2488

  Powderly, William G ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

AIDS; Antiretroviral therapy; Raltegravir

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; GSK 1349572; INTEGRASE; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; PLACEBO; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; PYRROLIDINONES;

EID: 78149492207     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq350     Document Type: Article

References (23)

1. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004; 4: 965-77.
2. Roquebert B, Damond F, Collin G et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008; 62: 914-20.
3. Steigbigel RT, Cooper DA, Teppler H et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50: 605-12.
4. Cooper D, Steigbigel R, Lennox J et al. Review of cancer incidence in raltegravir clinical trials. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montréal, Canada, 2009. Abstract 859. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
5. Markowitz M, Nguyen BY, Gotuzzo E et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52: 350-6.
6. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
7. Reynes J, Lawal A, Pulido F et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve HIV-1 infected subjects. In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract MOAB0101.
8. Kozal MJ, Lupo S, DeJesus E et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI-and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300 mg BID plus raltegravir (RAL) 400 mg BID (ATV+RAL) in treatment-naïve HIV-infected subjects. In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract THLBB204.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services, 1 December 2009; 1-61. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (20 July 2010, date last accessed).
10. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
11. Harris M, Larsen G, Montaner J. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS 2008; 22: 1224-6.
12. Towner W, Klein D, Kerrigan H et al. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. J Acquir Immune Defic Syndr 2009; 51: 367-73.
13. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407.
14. Martínez E, Larrousse M, Llibre JM et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697-707.
15. Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 2002; 185: 1251-60.
16. Ochoa de Echagüen A, Arnedo M, Xercavins M et al. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. AIDS 2005; 19: 1385-91.
17. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
18. Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54: 389-93.
19. Underwood M, St Clair M, Johns B et al. S/GSK1265744: a next generation integrase inhibitor (INI) with activity against raltegravirresistant clinical isolates. In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract MOAA0103.
20. Zolopa AR, Berger DS, Lampiris H et al. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 2010; 201: 814-22.
21. Lalezari J, Sloan L, DeJesus E et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naive HIV-1-infected patients. In: Abstracts of the Fifth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract TUAB105.
22. Arribas J, Lazzarin A, Raffi F et al. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276). In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract THLBB205.
23. Eron J, Durant J, Poizot-Martin I et al. Activity of a next generation integrase inhibitor (INI), S/GSK1349572, in subjects with HIV exhibiting raltegravir resistance: initial results of VIKING study (ING112961). In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract MOAB0105.